The interface between ErbB and non-ErbB receptors in tumor invasion: Clinical implications and opportunities for target discovery

Drug Resistance Updates

Volumn 6, Issue 2, 2003, Pages 95-107

  Alaoui Jamali, Moulay A ^a   Qiang, He ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

ErbB receptors; Experimental therapeutics; Non ErbB receptors; Signal transduction; Tumor microenvironment

Indexed keywords

ALPHA CATENIN; ANGIOGENESIS INHIBITOR; CATENIN; CETUXIMAB; COLLAGEN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FOCAL ADHESION KINASE; GEFITINIB; INTEGRIN; MED 1522; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY LM 609; NEU DIFFERENTIATION FACTOR; NOCODAZOLE; PACLITAXEL; PROTEIN CDC42; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; RAC PROTEIN; RECEPTOR SUBUNIT; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRASTUZUMAB; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ACTIN FILAMENT; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CELL; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MANIPULATION; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CELL ULTRASTRUCTURE; CLINICAL TRIAL; COMPLEX FORMATION; CYTOSKELETON; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; FOCAL ADHESION; HUMAN; LIGAND BINDING; METASTASIS; MICROFILAMENT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0037879057     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(03)00024-4     Document Type: Review

References (175)

1. Abedi, H., Zachary, I., 1997. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 272, 15442-15451.
2. Adam, L., Vadlamudi, R., Kondapaka, S.B., Chernoff, J., Mendelsohn, J., Kumar, R., 1998. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 273, 28238-28246.
3. Adelsman, M.A., McCarthy, J.B., Shimizu, Y., 1999. Stimulation of betal-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol. Biol. Cell 10, 2861-2878.
4. Aguilar, Z., Akita, R.W., Finn, R.S., et al., 1999. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18, 6050-6062.
5. Al Moustafa, A.E., Alaoui-Jamali, M.A., Batist, G., Hernandez-Perez, M., Serruya, C., Alpert, L., Black, M.J., Sladek, R., Foulkes, W.D., 2002a. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 21, 2634-2640.
6. Al Moustafa, A.E., Yansouni, C., Alaoui-Jamali, M.A., O'Connor-McCourt, M., 1999. Up-regulation of E-cadherin by an anti-epidermal growth factor receptor monoclonal antibody in lung cancer cell lines. Clin. Cancer Res. 5, 681-686.
7. Al Moustafa, A.E., Yen, L., Benlimame, N., Alaoui-Jamali, M.A., 2002b. Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 37, 49-56.
8. Albanell, J., Baselga, J., 2001. Unraveling resistance to trastuzumab (Hereeptin): insulin-like growth factor-I receptor, a new suspect. J. Natl. Cancer Inst. 93, 1830-1832.
9. Arteaga, C.L., 2002. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 4 (Suppl.), 31-39.
10. Auersperg, N., Pan, J., Grove, B.D., Peterson, T., Fisher, J., Maines-Bandiera, S., Somasiri, A., Roskelley, C.D., 1999. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc. Natl. Acad. Sci. U.S.A. 96, 6249-6254.
11. Balana, M.E., Labriola, L., Salatino, M., Movsichoff, F., Peters, G., Charreau, E.H., Elizalde, P.V., 2001. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20, 34-47.
12. Bardelli, A., Basile, M.L., Audero, E., Giordano, S., Wennstrom, S., Menard, S., Comoglio, P.M., Ponzetto, C., 1999. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene 18, 1139-1146.
13. Baudino, T.A., McKay, C., Pendeville-Samain, H., et al., 2002. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16, 2530-2543.
14. Bell, R., 2002. What can we learn from Herceptin trials in metastatic breast cancer? Oncology 1 (Suppl.), 39-46.
15. Biscardi, J.S., Denhez, F., Buehler, G.F., et al., 1996. Rek, a gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl/Tyro3 family. J. Biol. Chem. 271, 29049-29059.
16. Bissell, M.J., Weaver, V.M., Lelievre, S.A., Wang, F., Petersen, O.W., Schmeichel, K.L., 1999. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 59 (7 Suppl.), 1757s-1763s, discussion 1763s-1764s.
17. Blasi, F., Carmeliet, P., 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943.
18. Bocci, G., Nicolaou, K.C., Kerbel, R.S., 2002. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62, 6938-6943.
19. Bonvini, P., An, W.G., Rosolen, A., Nguyen, P., Trepel, J., Garcia de Herreros, A., Dunach, M., Neckers, L.M., 2001. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer Res. 61, 1671-1677.
20. Bos, J.L., Franke, B., M'Rabet, L., Reedquist, K., Zwartkruis, F., 1997. In search of a function for the Ras-like GTPase Rapl. FEBS Lett. 410, 59-62.
21. Browder, T., Butterfield, C.E., Kraling, B.M., Shi, B., Marshall, B., O'Reilly, M.S., Folkman, J., 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886.
22. Brunton, V.G., Ozanne, B.W., Paraskeva, C., Frame, M.C., 1997. A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene 14, 283-293.
23. Carneiro, F., Sobrino-Simoes, M., 2000. The prognostic significance of amplification and overexpression of c-met and c-erB-2 in human gastric carcinoma. Cancer 88, 238-240.
24. Carpenter, G., 1999. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J. Cell Biol. 146, 697-702.
25. Carraway, C.A., Carvajal, M.E., Carraway, K.L., 1999. Association of the Ras to mitogen-activated protein kinase signal transduction pathway with microfilaments. Evidence for a p185(neu)-containing cell surface signal transduction particle linking the mitogenic pathway to a membrane-microfilament association site. J. Biol. Chem. 274, 25659-25667.
26. Carraway, C.A., Carvajal, M.E., Li, Y., Carraway, K.L., 1993. Association of p185neu with microfilaments via a large glycoprotein complex in mammary carcinoma microvilli. Evidence for a microfilament-associated signal transduction particle. J. Biol. Chem. 268, 5582-5587.
27. Carraway, 3rd, K.L., Cantley, L.C., 1994. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78, 5-8.
28. Chan, K.C., Knox, W.F., Gee, J.M., Morris, J., Nicholson, R.I., Potten, C.S., Bundred, N.J., 2002. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 62, 122-128.
29. Chandrasekar, N., Mohanam, S., Gujrati, M., Olivero, W.C., Dinh, D.H., Rao, J.S., 2003. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene 22, 392-400.
30. Chausovsky, A., Tsarfaty, I., Kam, Z., Yarden, Y., Geiger, B., Bershadsky, A.D., 1998. Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. Mol. Biol. Cell 9, 3195-3209.
31. Chausovsky, A., Waterman, H., Elbaum, M., Yarden, Y., Geiger, B., Bershadsky, A.D., 2000. Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization. Oncogene 19, 878-888.
32. Chen, Q., Lin, T.H., Der, C.J., Juliano, R.L., 1996. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras. J. Biol. Chem. 271, 18122-18127.
33. Christofori, G., Semb, H., 1999. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 24, 73-76.
34. Countaway, J.L., Girones, N., Davis, R.J., 1989. Reconstitution of epidermal growth factor receptor transmodulation by platelet-derived growth factor in Chinese hamster ovary cells. J. Biol. Chem. 264, 13642-13647.
35. Dankort, D.L., Muller, W.J., 2000. Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene 19, 1038-1044.
36. Daub, H., Wallasch, C., Lankenau, A., Herrlich, A., Ullrich, A., 1997. Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 16, 7032-7044.
37. Daub, H., Weiss, F.U., Lankenau, A., Wellasch, C., Ullrich, A., 1996. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557-560.
38. De Bono, J.S., Rowinsky, E.K., 2002. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 4 (Suppl.), S19-S26.
39. Decker, S.J., Harris, P., 1989. Effects of platelet-derived growth factor on phosphorylation of the epidermal growth factor receptor in human skin fibroblasts. J. Biol. Chem. 264, 9204-9209.
40. Deng, G., Lu, Y., Zlotnikov, G., Thor, A.D., Smith, H.S., 1996. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274, 2057-2059.
41. Dittadi, R., Gion, M., 2000. More about prognostic importance of low c-erbB2 expression in breast tumors. J. Natl. Cancer Inst. 92, 1443-1444.
42. Dumont, J.E., Dremier, S., Pirson, I., Maenhaut, C., 2002. Cross signaling, cell specificity, and physiology. Am. J. Physiol. Cell Physiol. 283, C2-C28.
43. Eriksson, U., Alitalo, K., 1999. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curt. Top. Microbiol. Immunol. 237, 41-57.
44. Feldner, J.C., Brandt, B.H., 2002. Cancer cell motility - on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp. Cell Res. 272, 93-108.
45. Ferrara, N., 2002. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803.
46. Ferrero-Pous, M., Hacene, K., Tubiana-Hulin, M., Spyratos, F., 1999. Re: Prognostic importance of low c-erbB2 expression in breast tumors. J. Natl. Cancer Inst. 91, 1584-1585.
47. Folkman, J., 1990. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev. 9, 171-174.
48. Frisch, S.M., Vuori, K., Ruoslahti, E., Chan-Hui, P.Y., 1996. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 134, 793-799.
49. Gambaletta, D., Marchetti, A., Benedetti, L., Mercurio, A.M., Sacchi, A., Falcioni, R., 2000. Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidy-linositol 3-kinase-dependent invasion. J. Biol. Chem. 275, 10604-10610.
50. Giancotti, F.G., Ruoslahti, E., 1999. Integrin signaling. Science 285, 1028-1032.
51. Giordano, S., Bardelli, A., Zhen, Z., Menard, S., Ponzetto, C., Comoglio, P.M., 1997. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl. Acad. Sci. U.S.A. 94, 13868-13872.
52. Goldman, C.K., Kim, J., Wong, W.L., King, V., Brock, T., Gillespie, G.Y., 1993. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4, 121-133.
53. Grothey, A., Hashizume, R., Ji, H., et al., 2000. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19, 4864-4875.
54. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., Marme, D., 1995. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270, 25915-25919.
55. Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., Ullrich, A., 2001. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20, 1594-1600.
56. Gu, J., Tamura, M., Pankov, R., Danen, E.H., Takino, T., Matsumoto, K., Yamada, K.M., 1999. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 146, 389-403.
57. Gupta, R.A., Dubois, R.N., 2001. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1, 11-21.
58. Guvakova, M.A., Surmacz, E., 1999. The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin. Exp. Cell Res. 251, 244-255.
59. Hamaguchi, M., Matsuyoshi, N., Ohnishi, Y., Gotoh, B., Takeichi, M., Nagai, Y., 1993. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J. 12, 307-314.
60. Hanahan, D., Bergers, G., Bergsland, E., 2000. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047.
61. Hapke, S., Kessler, H., Arroyo de Prada, N., Benge, A., Schmitt, M., Lengyel, E., Reuning, U., 2001. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J. Biol. Chem. 276, 26340-26348.
62. Hauck, C.R., Sieg, D.J., Hsia, D.A., Loftus, J.C., Gaarde, W.A., Monia, B.P., Schlaepfer, D.D., 2001. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res. 61, 7079-7090.
63. Hazan, R.B., Phillips, G.R., Qiao, R.F., Norton, L., Aaronson, S.A., 2000. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 148, 779-790.
64. Heidkamp, M.C., Bayer, A.L., Kalina, J.A., Eble, D.M., Samarel, A.M., 2002. GFP-FRNK disrupts focal adhesions and induces anoikis in neonatal rat ventricular myocytes. Circ. Res. 90, 1282-1289.
65. Herbst, R.S., Kies, M.S., 2002. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 4 (Suppl.), 9-15.
66. Hintermann, E., Bilban, M., Sharabi, A., Quaranta, V., 2001. Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin. J. Cell Biol. 153, 465-478.
67. Ilic, D., Furuta, Y., Kanazawa, S., et al., 1995. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544.
68. Irby, R.B., Yeatman, T.J., 2000. Role of Src expression and activation in human cancer. Oncogene 19, 5636-5642.
69. Irby, R.B., Mao, W., Coppola, D., et al., 1999. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21, 187-190.
70. Itoh, K., Yoshioka, K., Akedo, H., Uehata, M., Ishizaki, T., Narumiya, S., 1999. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 5, 221-225.
71. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., Jain, R.K., 2002. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280.
72. Jo, M., Thomas, K.S., O'Donnell, D.M., Gonias, S.L., 2003. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278, 1642-1646.
73. Jung, Y.D., Mansfield, P.F., Akagi, M., et al., 2002. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur. J. Cancer 38, 1133-1140.
74. Kaetzel, D.M., Reid, 4th, J.D., Pedigo, N., Zimmer, S.G., Boghaert, E.R., 1998. A dominant-negative mutant of the platelet-derived growth factor A-chain increases survival of hamsters implanted intracerebrally with the highly invasive CxT24-neo3 glioblastoma cell. J. Neurooncol. 39, 33-46.
75. Kanai, Y., Ochiai, A., Shibata, T., Oyama, T., Ushijima, S., Akimoto, S., Hirohashi, S., 1995. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem. Biophys. Res. Commun. 208, 1067-1072.
76. Kerbel, R., Folkman, J., 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-739.
77. Kerbel, R.S., Klement, G., Pritchard, K.I., Kamen, B., 2002. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol. 13, 12-15.
78. Klement, G., Baruchel, S., Rak, J., et al., 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, 15-24.
79. Klement, G., Huang, P., Mayer, B., et al., 2002. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8, 221-232.
80. Kim, H., Muller, W.J., 1999. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253, 78-87.
81. Koscielny, S., Terrier, P., Daver, A., et al., 1998a. Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. Eur. J. Cancer 34, 476-481.
82. Koscielny, S., Terrier, P., Spielmann, M., Delarue, J.C., 1998b. Prognostic importance of low c-erbB2 expression in breast tumors. J. Natl. Cancer Inst. 90, 712.
83. Kroschewski, R., Hall, A., Mellman, I., 1999. Cdc42 controls secretory and endocytic transport to the basolateral plasma membrane of MDCK cells. Nat. Cell Biol. 1, 8-13.
84. LaRochelle, W.J., Jeffers, M., Corvalan, J.R., et al., 2002. Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. Cancer Res. 62, 2468-2473.
85. Lee, T.Y., Gotlieb, A.I., 2003. Microfilaments and microtubules maintain endothelial integrity. Microsc. Res. Tech. 60, 115-127.
86. Leventhal, P.S., Shelden, E.A., Kim, B., Feldman, E.L., 1997. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance. J. Biol. Chem. 272, 5214-5218.
87. Levkowitz, G., Klapper, L.N., Tzahar, E., Freywald, A., Sela, M., Yarden, Y., 1996. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12, 1117-1125.
88. Li, J., Kim, Y.N., Bertics, P.J., 2000. Platelet-derived growth factor-stimulated migration of murine fibroblasts is associated with epidermal growth factor receptor expression and tyrosine phosphorylation. J. Biol. Chem. 275, 2951-2958.
89. Li, M., Ye, C., Feng, C., Riedel, F., Liu, X., Zeng, Q., Grandis, J.R., 2002. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin. Cancer Res. 8, 3570-3578.
90. Li, Y., Hua, F., Carraway, K.L., Carraway, C.A., 1999. The p185(neu)-containing glycoprotein complex of a microfilament-associated signal transduction particle. Purification, reconstitution, and molecular associations with p58(gag) and actin. J. Biol. Chem. 274, 25651-25658.
91. Liekens, S., De Clercq, E., Neyts, J., 2001. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61, 253-270.
92. Liu, D., Aguirre Ghiso, J., Estrada, Y., Ossowski, L., 2002. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457.
93. Lopez, T., Hanahan, D., 2002. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1, 339-353.
94. Lu, Z., Jiang, G., Blume-Jensen, P., Hunter, T., 2001. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol. Cell. Biol. 21, 4016-4031.
95. Luttrell, L.M., Daaka, Y., Lefkowitz, R.J., 1999. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11, 177-183.
96. Maa, M.C., Leu, T.H., McCarley, D.J., Schatzman, R.C., Parsons, S.J., 1995. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. U.S.A. 92, 6981-6985.
97. Man, S., Bocci, G., Francia, G., et al., 2002. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62, 2731-2735.
98. Mann, M., Sheng, H., Shao, J., Williams, C.S., Pisacane, P.I., Sliwkowski, M.X., DuBois. R.N., 2001. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120, 1713-1719.
99. Martin, K.H., Boemer, S.A., Parsons, J.T., 2002. Regulation of focal adhesion targeting and inhibitory functions of the FAK related protein FRNK using a novel estrogen receptor "switch". Cell. Motil. Cytoskeleton. 51, 76-88.
100. Matsumoto, K., Matsumoto, K., Nakamura, T., Kramer, R.H., 1994. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem. 269, 31807-31813.
101. Mauro, L., Salerno, M., Morelli, C., Boterberg, T., Bracke, M.E., Surmacz, E., 2003. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J. Cell. Physiol. 194, 108-116.
102. Mendelsohn, J., Baselga, J., 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565.
103. Miller, K.D., Sweeney, C.J., Sledge, Jr., G.W., 2001. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19, 1195-1206.
104. Miyamoto, S., Teramoto, H., Coso, O.A., Gutkind, J.S., Burbelo, P.D., Akiyama, S.K., Yamada, K.M., 1995. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J. Cell Biol. 131, 791-805.
105. Miyamoto, S., Teramoto, H., Gutkind, J.S., Yamada, K.M., 1996. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J. Cell Biol. 135, 1633-1642.
106. Moro, L., Dolce, L., Cabodi, S., et al., 2002. Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J. Biol. Chem. 277, 9405-9414.
107. Moro, L., Venturino, M., Bozzo, C., et al., 1998. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 17, 6622-6632.
108. Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F., Arteaga, C.L., 2001. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887-8895.
109. Mross, K., 2000. Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials. Drug Resist. Updates 3, 223-235.
110. Mukhopadhyay, D., Tsiokas, L., Zhou, X.M., Foster, D., Brugge, J.S., Sukhatme, V.P., 1995. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577-581.
111. Nicholson, R.I., Gee, J.M., Harper, M.E., 2001. EGFR and cancer prognosis. Eur. J. Cancer 4 (Suppl.), S9-S15.
112. Novatchkova, M., Eisenhaber, E, 2001. Can molecular mechanisms of biological processes be extracted from expression profiles? Case study: endothelial contribution to tumor-induced angiogenesis. Bioessays 23, 1159-1175.
113. Ochiai, A., Akimoto, S., Kanai, Y., Shibata, T., Oyama, T., Hirohashi, S., 1994. c-erbB-2 gene product associates with catenins in human cancer cells. Biochem. Biophys. Res. Commun. 205, 73-78.
114. O'Connor, K.L., Shaw, L.M., Mercurio, A.M., 1998. Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells. J. Cell Biol. 143, 1749-1760.
115. Oft, M., Akhurst, R.J., Balmain, A., 2002. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4, 487-494.
116. Olayioye, M.A., Neve, R.M., Lane, H.A., Hynes, N.E., 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167.
117. Ouwens, D.M., Mikkers, H.M., van der Zon, G.C., Stein-Gerlach, M., Ullrich, A., Maassen, J.A., 1996. Insulin-induced tyrosine dephosphorylation of paxillin and focal adhesion kinase requires active phosphotyrosine phosphatase 1D. Biochem. J. 318, 609-614.
118. Perl, A.K., Wilgenbus, P., Dahl, U., Semb, H., Christofori, G., 1998. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392, 190-193.
119. Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B., Kerbel, R.S., 1997. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523-1530.
120. Pollack, I.F., Bredel, M., Erff, M., Hamilton, A.D., Sebti, S.M., 1999. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II preclinical studies in a nude mouse model. Neurosurgery 45, 1208-1214, discussion 1214-1215.
121. Polverini, P.J., Novak, R.F., 1986. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene. Biochem. Biophys. Res. Commun. 140, 901-907.
122. Prendergast, G.C., Du, W., 1999. Targeting farnesyltransferase: is Ras relevant? Drug Resist. Updates 2, 81-84.
123. Qiu, Y., Ravi, L., Kung, H.J., 1998. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393, 83-85.
124. Rak, J., Mitsuhashi, Y., Sheehan, C., et al., 2000. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60, 490-498.
125. Richardson, A., Parsons, T., 1996. A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125FAK. Nature 380, 538-540.
126. Ridley, A.J., Hall, A., 1992. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389-399.
127. Ridley, A.J., Paterson, H.F., Johnston, C.L., Diekmann, D., Hall, A., 1992. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70, 401-410.
128. Riese, 2nd, D.J., Stem, D.F., 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20, 41-48.
129. Rosenberg, S., 2001. New developments in the urokinase-type plasminogen activator system. Expert Opin. Ther. Targets 5, 711-722.
130. Rosenthal, E.L., Johnson, T.M., Allen, E.D., Apel, I.J., Punturieri, A., Weiss, S.J., 1998. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res. 58, 5221-5230.
131. Rusnati, M., Tanghetti, E., Dell'Era, P., Gualandris, A., Presta, M., 1997. Alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol. Biol. Cell. 8, 2449-2461.
132. Sahai, E., Marshall, C.J., 2002. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 4, 408-415.
133. Saito, Y., Haendeler, J., Hojo, Y., Yamamoto, K., Berk, B.C., 2001. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol. Cell Biol. 21, 6387-6394.
134. Schaller, M.D., Hildebrand, J.D., Shannon, J.D., Fox, J.W., Vines, R.R., Parsons, J.T., 1994. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol. Cell Biol. 14, 1680-1688.
135. Schlaepfer, D.D., Hanks, S.K., Hunter, T., van der Geer, P., 1994. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 372, 786-791.
136. Schlaepfer, D.D., Hauck, C.R., Sieg, D.J., 1999. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 71, 435-478.
137. Schneller, M., Vuori, K., Ruoslahti, E., 1997. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J. 16, 5600-5607.
138. Schroeder, J.A., Adriance, M.C., McConnell, E.J., Thompson, M.C., Pockaj, B., Gendler, S.J., 2002. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J. Biol. Chem. 277, 22692-22698.
139. Schwartz, M.A., Baron, V., 1999. Interactions between mitogenic stimuli, or, a thousand and one connections. Curr. Opin. Cell Biol. 11, 197-202.
140. Semenza, G.L., 2000. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19, 59-65.
141. Sheta, E.A., Harding, M.A., Conaway, M.R., Theodorescu, D., 2000. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J. Natl. Cancer Inst. 92, 1065-1073.
142. Sieg, D.J., Hauck, C.R., Ilic, D., Klingbeil, C.K., Schaefer, E., Damsky, C.H., Schlaepfer, D.D., 2000. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2, 249-256.
143. Sieg, D.J., Hauck, C.R., Schlaepfer, D.D., 1999. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J. Cell Sci. 112, 2677-2691.
144. Siegel, P.M., Ryan, E.D., Cardiff, R.D., Muller, W.J., 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18, 2149-2164.
145. Slamon, D., Pegram, M., 2001. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 28 (1 (Suppl. 3)), 13-19.
146. Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G., Bussolino, F., 1999. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 18, 882-892.
147. Somlyo, A.V., Bradshaw, D., Ramos, S., Murphy, C., Myers, C.E., Somlyo, A.P., 2000. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 269, 652-659.
148. Steller, M.A., Delgado, C.H., Zou, Z., 1995. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. Proc. Natl. Acad. Sci. U.S.A. 92, 11970-11974.
149. Sturge, J., Hamelin, J., Jones, G.E., 2002. N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator. J. Cell Sci. 115, 699-711.
150. Suo, Z., Risberg, B., Kalsson, M.G., Willman, K., Tierens, A., Skovlund, E., Nesland, J.M., 2002. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol. 196, 17-25.
151. Takata, M., Fujimoto, A., Aoki, H., Hatta, N., Ooi, A., Takehara, K., 1999. ErbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease. J. Invest. Dermatol. 113, 258-262.
152. Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R., Yamada, K.M., 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280, 1614-1617.
153. Tice, D.A., Biscardi, J.S., Nickles, A.L., Parsons, S.J., 1999. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. U.S.A. 96, 1415-1420.
154. Trusolino, L., Bertotti, A., Comoglio, P.M., 2001. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643-654.
155. Tyson, J.J., Csikasz-Nagy, A., Novak, B., 2002. The dynamics of cell cycle regulation. Bioessays 24, 1095-1109.
156. Vadlamudi, R.K., Adam, L., Nguyen, D., Santos, M., Kumar, R., 2002. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. J. Cell. Physiol. 190, 189-199.
157. Vartanian, T., Goodearl, A., Lefebvre, S., Park, S.K., Fischbach, G., 2000. Neuregulin induces the rapid association of focal adhesion kinase with the erbB2-erbB3 receptor complex in Schwann cells. Biochem. Biophys. Res. Commun. 271, 414-417.
158. Vastrik, I., Eickholt, B.J., Walsh, F.S., Ridley, A., Doherty, P., 1999. Sema3A-induced growth-cone collapse is mediated by Racl amino acids 17-32. Curr. Biol. 9, 991-998.
159. Venkateswarlu, S., Dawson, D.M., St Clair, P., Gupta, A., Willson, J.K., Brattain, M.G., 2002. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 21, 78-86.
160. Vial, D., Okazaki, H., Siraganian, R.P., 2000. The NH2-terminal region of focal adhesion kinase reconstitutes high affinity IgE receptor-induced secretion in mast cells. J. Biol. Chem. 275, 28269-28275.
161. Viloria-Petit, A., Crombet, T., Jothy, S., et al., 2001. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61, 5090-5101.
162. Vinals, F., Pouyssegur, J., 2001. Transforming growth factor betal
163. Vuori, K., Ruoslahti, E., 1994. Association of insulin receptor substrate-1 with integrins. Science 266, 1576-1578.
164. Walker, F., Burgess, A.W., 1991. Reconstitution of the high affinity epidermal growth factor receptor on cell-free membranes after transmodulation by platelet-derived growth factor. J. Biol. Chem. 266, 2746-2752.
165. Watkins, T.A., Barres, B.A., 2002. Integrins as developmental switches. Nat. Cell Biol. 4, E253-E255.
166. Weaver, V.M., Petersen, O.W., Wang, F., Larabell, C.A., Briand, P., Damsky, C., Bissell, M.J., 1997. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245.
167. Winder, S.J., 2003. Structural insights into actin-binding, branching and bundling proteins. Curr. Opin. Cell Biol. 15, 14-22.
168. Wong, A.J., Ruppert, J.M., Bigner, S.H., Grzeschik, C.H., Humphrey, P.A., Bigner, D.S., Vogelstein, B., 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U.S.A. 89, 2965-2969.
169. Xia, W., Lau, Y.K., Zhang, H.Z., et al., 1999. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin. Cancer Res. 5, 4164-4174.
170. Yamauchi, T., Ueki, K., Tobe, K., et al., 1997. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 390, 91-96.
171. Yarden, Y., Sliwkowski, M.X., 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137.
172. Yen, L., Benlimame, N., Nie, Z.R., et al., 2002. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol. Biol. Cell 13, 4029-4044.
173. Yen, L., You, X.L., Al Moustafa, A.E., Batist, G., Hynes, N.E., Mader, S., Meloche, S., Alaoui-Jamali, M.A., 2000. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19, 3460-3469.
174. Yu, H., Rohan, T., 2000. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 92, 1472-1489.
175. Zrihan-Licht, S., Lim, J., Keydar, I., Sliwkowski, M.X., Groopman, J.E., Avraham, H., 1997. Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells. J. Biol. Chem. 272, 1856-1863.